Skip to main content
GRML
NASDAQ Life Sciences

Shareholders Approve Reverse Stock Split to Address Nasdaq Delisting Threat

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$0.268
Mkt Cap
$32.498M
52W Low
$0.21
52W High
$1.67
52W Position info
28% above low
Off High info
84% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

GRML sits 28% above its 52-week low of $0.21.

Summary

Greenland Mines Ltd shareholders approved a reverse stock split, allowing the board to implement a ratio up to 1-for-60 to maintain Nasdaq listing amidst financial distress.


Key Events · Corporate Governance and Compliance · GRML

  • Reverse Stock Split Approved

    Shareholders voted to approve one or more reverse stock splits with an exchange ratio between 1-for-2 and 1-for-50, not to exceed 1-for-60 in aggregate.

  • Board Discretion on Implementation

    The Board of Directors has until March 31, 2027, to determine the exact timing and ratio of the reverse split(s).

  • Addresses Nasdaq Delisting Threat

    This approval is a direct response to the company's previously disclosed Nasdaq delisting threat due to its low share price, a critical step for continued listing.


Analysis · GRML · Life Sciences

Shareholders of Greenland Mines Ltd have approved a reverse stock split, a critical measure to address the company's low share price and avoid potential delisting from Nasdaq. This action is a necessary step in the company's ongoing efforts to stabilize its financial position and maintain its public listing, following previous disclosures of going concern doubts and delisting threats.

How filings like this one have moved

In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GRML was trading at $0.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.5M. The 52-week trading range was $0.21 to $1.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GRML - Latest Insights

GRML
Sep 08, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.84
Real-time Price: $3.20 info
Change: -$1.64 (-34%) info
Market Cap: $10.008M info
GRML
Sep 04, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.81
Real-time Price: $3.20 info
Change: -$1.61 (-33%) info
Market Cap: $10.008M info
GRML
Sep 03, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.87
Real-time Price: $3.20 info
Change: -$1.67 (-34%) info
Market Cap: $10.008M info
GRML
Sep 02, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.97
Real-time Price: $3.20 info
Change: -$1.77 (-36%) info
Market Cap: $10.008M info
GRML
Aug 28, 2026, 11:32 AM EDT
Source: FinanceWire
Importance Score:
8
Price at Filing: $5.16
Real-time Price: $3.20 info
Change: -$1.96 (-38%) info
Market Cap: $10.008M info